As of Apr 2, 2025, the Insulet stock's PE ratio is 45.08. This takes into account the latest EPS of $5.97 and stock price of $269.13. The PE ratio marks an increase of 7% from its last 4 quarters average of 42.3.
The PE ratio of Insulet has averaged 2204.46 over the last seven years. The current P/E ratio of 45.08 is 98% lower than the historical average. Looking back at the last seven years, PODD's PE ratio peaked in the Mar 2023 quarter at 31,896, when the price was $318.96 and the EPS was $0.01. The lowest point was in the Jun 2024 quarter, when it reached 35.72 with a price of $201.8 and an EPS of $5.65.
Maximum annual increase: 295.16% in 2022
Maximum annual decrease: -98.26% in 2023
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 43.73 | -40.34% | $261.07 | $5.97 |
2023 | 73.3 | -98.26% | $216.98 | $2.96 |
2022 | 4,205.57 | 295.16% | $294.39 | $0.07 |
2021 | 1,064.28 | -54.2% | $266.07 | $0.25 |
2020 | 2,323.91 | 157.91% | $255.63 | $0.11 |
2019 | 901.05 | -31.84% | $171.2 | $0.19 |
2018 | 1,322 | N/A | $79.32 | $0.06 |
2017 | N/A | N/A | $69 | -$0.46 |
2016 | N/A | N/A | $37.68 | -$0.51 |
2015 | N/A | N/A | $37.81 | -$1.29 |
2014 | N/A | N/A | $46.06 | -$0.92 |
2013 | N/A | N/A | $37.1 | -$0.83 |
2012 | N/A | N/A | $21.22 | -$1.08 |
2011 | N/A | N/A | $18.83 | -$0.98 |
2010 | N/A | N/A | $15.5 | -$1.54 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 43.73 | 13.11% | $261.07 | $5.97 |
Sep 2024 | 38.66 | 8.23% | $232.75 | $6.02 |
Jun 2024 | 35.72 | -30.18% | $201.8 | $5.65 |
Mar 2024 | 51.16 | -30.2% | $171.4 | $3.35 |
Dec 2023 | 73.3 | -20.95% | $216.98 | $2.96 |
Sep 2023 | 92.73 | -71.06% | $159.49 | $1.72 |
Jun 2023 | 320.38 | -99% | $288.34 | $0.9 |
Mar 2023 | 31,896 | 658.42% | $318.96 | $0.01 |
Dec 2022 | 4,205.57 | 358.32% | $294.39 | $0.07 |
Sep 2022 | 917.6 | 114.73% | $229.4 | $0.25 |
Jun 2022 | 427.33 | 2.67% | $217.94 | $0.51 |
Mar 2022 | 416.23 | -60.89% | $266.39 | $0.64 |
Dec 2021 | 1,064.28 | N/A | $266.07 | $0.25 |
Sep 2021 | N/A | N/A | $284.23 | -$0.45 |
Jun 2021 | N/A | N/A | $274.51 | -$0.45 |
PODD's current PE ratio is lower than its 3, 5 and 10-year averages.
PODD's PE ratio stands lower than its peer stocks LLY and DXCM, but it is higher than JNJ's and ABT's. Insulet is currently trading at a higher PE ratio (45.08) than its peers average of 37.38.
Stock name | PE ratio | Market cap |
---|---|---|
ABT Abbott Laboratories | 17.2 | $228.86B |
MDT Medtronic plc | 26.6 | $112.92B |
JNJ Johnson & Johnson | 27.3 | $383.85B |
PODD Insulet Corp | 42.32 | $17.74B |
DXCM Dexcom Inc | 42.56 | $24.28B |
LLY ELI LILLY & Co | 68.19 | $760.37B |
ICUI Icu Medical Inc | N/A | $3.47B |
DCTH Delcath Systems Inc | N/A | $400.84M |
TNDM Tandem Diabetes Care Inc | N/A | $1.18B |
PODD stock has a price to earnings ratio of 45.08 as of Apr 2, 2025.
The average PE ratio for PODD stock over the past 3 years is 3463.83.
The average PE ratio for PODD stock over the past 5 years is 2646.46.
Over the last seven years, the quarterly PE ratio reached its highest level at 31,896 in the Mar 2023 quarter.
PODD's price to earnings ratio is currently 98% below its 7-year historical average.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Apr 2, 2025), Insulet's share price is $269.13. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $5.97. Therefore, Insulet's PE ratio for today is 45.08. PE RATIO(45.08) = STOCK PRICE($269.13) / TTM EPS($5.97)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.